Drug Trial Radar · NCT03346837
A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Feb 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Nov 22, 2017
Primary completion
Dec 20, 2017
Study completion Dec 20, 2017
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Assess the effects of itraconazole and rifampin on the pharmacokinetics, safety, and tolerability of BMS-986205.
Conditions
- Malignancies Multiple
Interventions
BMS-986205Drug
BMS-986205
ItraconazoleDrug
Oral solution
RifampinDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Up to 25 days
- AUC from time zero to time of last quantifiable concentration (AUC(0-T))Time frame: Up to 25 days
- AUC from time zero extrapolated to infinite time (AUC(INF))Time frame: Up to 25 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.